Daiichi Sankyo generics' unit to launch 5 drugs
17 Dec 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Daiichi Sankyo's pharmaceuticals subsidiary, Daiichi Sankyo Espha is all set to launch five generic products Quetiapine tablets 25 mg DSEP, Quetiapine tablets 100 mg DSEP and Quetiapine tablets 200 mg DSEP.
Quetiapine is indicated for the treatment of anti-psychosis. Espha also launched Mosapride Citrate tablets 2.5 mg DSEP, Mosapride Citrate tablets 5 mg DSEP. Mosapride Citrate is indicated for the treatment of gastroprokinetic agent.
Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and to accommodate rising demand of diverse medical needs.
© Copyright © 2013 CyberMedia (I) Ltd All rights reserved.
Reproduction in whole or in part in any form or medium without written permission is prohibited.
Reproduction in whole or in part in any form or medium without written permission is prohibited.